♦ More than four million people in the developed world, including as many as 1.5 million in the US, mainly over the age of 65, are diagnosed with Parkinson's disease (PD). That figure is predicted to rise by 10% by 2010.
♦ PD drugs with a combined annual market value of approximately $3 billion are insufficient to meet patient needs.
♦ Recent significant product approvals in PD include Schwarz Pharma's transdermal patch Neupro (rotigotine); Teva's monoamine oxidase type b inhibitor, Azilect (rasagiline); and Novartis's reversible cholinesterase inhibitor, Exelon (rivastigmine tartrate), the first drug approved in the US for mild to moderate dementia associated with the disease.
♦ Table 2 lists selected recent regulatory submissions and actions regarding PD therapeutics.
♦ Table 3 lists selected PD therapeutics - dopaminergic and non-dopaminergic - in Phase III development; Table 4 lists those in Phase II.